{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:03:40Z","timestamp":1791925420607,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.vaccine.2005.03.037","type":"journal-article","created":{"date-parts":[[2005,5,6]],"date-time":"2005-05-06T19:34:36Z","timestamp":1115408076000},"page":"4101-4109","source":"Crossref","is-referenced-by-count":100,"title":["Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses"],"prefix":"10.1016","volume":"23","author":[{"given":"S.M.","family":"Brookes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"McElhinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Fooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2005.03.037_bib1","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1128\/JCM.30.9.2419-2426.1992","article-title":"Antigenic and molecular characterization of bat rabies virus in Europe","volume":"30","author":"Bourhy","year":"1992","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2005.03.037_bib2","first-page":"268","article-title":"Cross protection of mice against different rabies virus isolates","volume":"259","author":"Larghi","year":"1985","journal-title":"Zentralbl Bakteriol Mikrobiol Hyg [A]"},{"key":"10.1016\/j.vaccine.2005.03.037_bib3","series-title":"Rabies in the tropic","first-page":"30","article-title":"Cross-reactivity and cross-protection: rabies variants and rabies-related viruses","author":"Koprowski","year":"1985"},{"issue":"7","key":"10.1016\/j.vaccine.2005.03.037_bib4","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1128\/JVI.75.7.3268-3276.2001","article-title":"Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity","volume":"75","author":"Badrane","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2005.03.037_bib5","first-page":"101","article-title":"The unusual bat Lyssavirus Aravan from Central Asia","volume":"34","author":"Botvinkin","year":"1996","journal-title":"Myotis"},{"issue":"12","key":"10.1016\/j.vaccine.2005.03.037_bib6","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3201\/eid0912.030374","article-title":"Novel Lyssaviruses isolated from bats in Russia","volume":"9","author":"Botvinkin","year":"2003","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2005.03.037_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid0903.020252","article-title":"New Lyssavirus genotype from the lesser mouse-eared bat (Myotis blythi), Kyrghyzstan","volume":"9","author":"Arai","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2005.03.037_bib8","unstructured":"WHO 9th report. The expert consultation on rabies with the participation of the network of WHO Collaborating Centers on Rabies was held in Geneva 5\u20138 October 2004, http:\/\/www.who.int\/rabies\/resources\/en\/."},{"key":"10.1016\/j.vaccine.2005.03.037_bib9","doi-asserted-by":"crossref","unstructured":"Anon. MMWR 1999;48(RR-1):1\u201321.","DOI":"10.1093\/library\/21.1.91"},{"key":"10.1016\/j.vaccine.2005.03.037_bib10","first-page":"173","article-title":"Current and future immunoprophylaxis against human rabies: reduction of treatment failures and errors","volume":"187","author":"Thraenhart","year":"1994","journal-title":"Curr Top Microbiol Immunol"},{"issue":"9413","key":"10.1016\/j.vaccine.2005.03.037_bib11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(04)15792-9","article-title":"Rabies and other lyssavirus diseases","volume":"363","author":"Warrell","year":"2004","journal-title":"Lancet"},{"issue":"1\u20133","key":"10.1016\/j.vaccine.2005.03.037_bib12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0147-9571(82)90021-2","article-title":"Antigenic variants of rabies virus","volume":"5","author":"Schneider","year":"1982","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2005.03.037_bib13","first-page":"279","article-title":"Laboratory techniques in rabies: the NIH test for potency","volume":"23","author":"Seligmann","year":"1973","journal-title":"Monogr Ser World Health Organ"},{"issue":"8","key":"10.1016\/j.vaccine.2005.03.037_bib14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0966-842X(93)90010-O","article-title":"Avirulent mutants of rabies virus and their use as live vaccine","volume":"1","author":"Flamand","year":"1993","journal-title":"Trends Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2005.03.037_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0092-1157(89)90018-8","article-title":"Effect of strain differences on the potency testing of rabies vaccines in mice","volume":"17","author":"Blancou","year":"1989","journal-title":"J Biol Stand"},{"issue":"8","key":"10.1016\/j.vaccine.2005.03.037_bib16","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1128\/JVI.69.8.4957-4962.1995","article-title":"Cross-protection of mice against a global spectrum of rabies virus variants","volume":"69","author":"Lodmell","year":"1995","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2005.03.037_bib17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2460\/ajvr.2003.64.491","article-title":"Effects of vaccine route and dosage on protection from rabies after intracerebral challenge in mice","volume":"64","author":"Wunderli","year":"2003","journal-title":"Am J Vet Res"},{"issue":"4","key":"10.1016\/j.vaccine.2005.03.037_bib18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2460\/ajvr.2003.64.499","article-title":"Effect of heterogeneity of rabies virus strain and challenge route on efficacy of inactivated rabies vaccines in mice","volume":"64","author":"Wunderli","year":"2003","journal-title":"Am J Vet Res"},{"issue":"6","key":"10.1016\/j.vaccine.2005.03.037_bib19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0264-410X(88)90098-9","article-title":"Comparative study of two human diploid rabies vaccines administered with antirabies globulin","volume":"6","author":"Vodopija","year":"1988","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2005.03.037_bib20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2249.1991.tb05709.x","article-title":"T and B cell human responses to European bat Lyssavirus after post-exposure rabies vaccination","volume":"85","author":"Herzog","year":"1991","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2005.03.037_bib21","first-page":"271","article-title":"Rabies virus antigenicity: an overview","volume":"60","author":"Coulon","year":"1993","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.vaccine.2005.03.037_bib22","first-page":"R1","article-title":"Can vaccination validated by the titration of rabies antibodies in serum of cats and dogs be an alternative to quarantine measures","volume":"68","author":"Aubert","year":"1993","journal-title":"Abstr Hyg Commun Dis"},{"key":"10.1016\/j.vaccine.2005.03.037_bib23","series-title":"Laboratory techniques in rabies","first-page":"114","article-title":"Cell culture of rabies virus","author":"King","year":"1996"},{"key":"10.1016\/j.vaccine.2005.03.037_bib24","series-title":"Laboratory techniques in rabies","first-page":"80","article-title":"The mouse inoculation test","author":"Koprowski","year":"1996"},{"issue":"1","key":"10.1016\/j.vaccine.2005.03.037_bib25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0022-1759(97)00212-3","article-title":"Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody","volume":"212","author":"Cliquet","year":"1998","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2005.03.037_bib26","unstructured":"Office International des Epizooties. Rabies. In: Manual of standards\u2014diagnostic tests and vaccines. 4th ed. 2000, http:\/\/www.oie.int\/eng\/normes\/mmanual\/A_00042.htm."},{"key":"10.1016\/j.vaccine.2005.03.037_bib27","series-title":"Laboratory techniques in rabies","article-title":"The NIH test for potency","author":"Wilbur","year":"1996"},{"issue":"1","key":"10.1016\/j.vaccine.2005.03.037_bib28","first-page":"37","article-title":"Clinical endpoints during rabies vaccine control tests","volume":"18","author":"Hartinger","year":"2001","journal-title":"ALTEX"},{"key":"10.1016\/j.vaccine.2005.03.037_bib29","series-title":"Laboratory techniques in rabies","first-page":"88","article-title":"The fluorescent antibody test","author":"Dean","year":"1996"},{"issue":"11","key":"10.1016\/j.vaccine.2005.03.037_bib30","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1128\/JCM.35.11.2762-2766.1997","article-title":"Heminested PCR assay for detection of six genotypes of rabies and rabies-related viruses","volume":"35","author":"Heaton","year":"1997","journal-title":"J Clin Microbiol"},{"issue":"11","key":"10.1016\/j.vaccine.2005.03.037_bib31","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00705-002-0877-4","article-title":"Phylogenetic comparison of the genus Lyssavirus using distal coding sequences of the glycoprotein and nucleoprotein genes","volume":"147","author":"Johnson","year":"2002","journal-title":"Arch Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2005.03.037_bib32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0264-410X(85)90224-5","article-title":"Rabies immunosome (subunit vaccine) structure and immunogenicity. Pre- and post-exposure protection studies","volume":"3","author":"Perrin","year":"1985","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2005.03.037_bib33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4049\/jimmunol.110.1.269","article-title":"Antigenic properties of rabies virus components","volume":"110","author":"Wiktor","year":"1973","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2005.03.037_bib34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1073\/pnas.74.1.334","article-title":"In vitro evidence of cell-mediated immunity after exposure of mice to both live and inactivated rabies virus","volume":"74","author":"Wiktor","year":"1977","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.vaccine.2005.03.037_bib35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0923-2516(96)82287-4","article-title":"The antigen-specific cell-mediated immune response in mice is suppressed by infection with pathogenic lyssaviruses","volume":"147","author":"Perrin","year":"1996","journal-title":"Res Virol"},{"key":"10.1016\/j.vaccine.2005.03.037_bib36","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1099\/0022-1317-70-6-1513","article-title":"Rabies virus-specific human T cell clones provide help for an in vitro antibody response against neutralizing antibody-inducing determinants of the viral glycoprotein","volume":"70","author":"Bunschoten","year":"1989","journal-title":"J Gen Virol"},{"issue":"1\u20133","key":"10.1016\/j.vaccine.2005.03.037_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0147-9571(82)90021-2","article-title":"Antigenic variants of rabies virus","volume":"5","author":"Schneider","year":"1982","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2005.03.037_bib38","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/infdis\/156.5.815","article-title":"Antigenic variation in rabies and rabies-related viruses: cross-protection independent of glycoprotein-mediated virus-neutralizing antibody","volume":"156","author":"Dietzschold","year":"1987","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2005.03.037_bib39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0264-410X(88)90107-7","article-title":"Efficacy of rabies vaccines against Duvenhage virus isolated from European house bats (Eptesicus serotinus), classic rabies and rabies-related viruses","volume":"6","author":"Fekadu","year":"1988","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2005.03.037_bib40","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/0264-410X(88)90184-3","article-title":"Immunity against the European bat rabies (Duvenhage) virus induced by rabies vaccines: an experimental study in mice","volume":"6","author":"Lafon","year":"1988","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2005.03.037_bib41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1128\/JVI.73.1.225-233.1999","article-title":"Chimeric Lyssavirus glycoproteins with increased immunological potential","volume":"73","author":"Jallet","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2005.03.037_bib42","series-title":"Bats and rabies","first-page":"75","article-title":"Bat rabies: pathogenesis and vaccine efficacy","author":"Fekadu","year":"1993"},{"key":"10.1016\/j.vaccine.2005.03.037_bib43","unstructured":"Hanlon CA, Kuzmin I, Blanton J, Manangan J, Murphy SM, Rupprecht CE. Efficacy of biologics against newly described lyssaviruses. In: Proceedings of 14th International conference on Rabies in the Americas, October 2003, p. 55\u201356."},{"key":"10.1016\/j.vaccine.2005.03.037_bib44","doi-asserted-by":"crossref","unstructured":"Brookes SM, Aegerter JN, Smith GC, Healy DM, Jolliffe TA, Swift SM, et al. European bat lyssavirus in Scottish bats. Emerg Infect Dis [serial on the Internet]. 2005 April [date cited], http:\/\/www.cdc.gov\/ncidod\/EID\/vol11no04\/04-0920.htm.","DOI":"10.3201\/eid1104.040920"},{"issue":"28\u201329","key":"10.1016\/j.vaccine.2005.03.037_bib45","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1016\/S0264-410X(01)00135-9","article-title":"Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis","volume":"19","author":"Hanlon","year":"2001","journal-title":"Vaccine"},{"issue":"Pt 8","key":"10.1016\/j.vaccine.2005.03.037_bib46","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1099\/0022-1317-64-8-1649","article-title":"Rabies subunit vaccines","volume":"64","author":"Wunner","year":"1983","journal-title":"J Gen Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2005.03.037_bib47","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/0264-410X(91)90188-C","article-title":"The protective role of humoral neutralizing antibody in the NIH potency test for rabies vaccines","volume":"9","author":"Wunderli","year":"1991","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2005.03.037_bib48","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/infdis\/136.3.336","article-title":"Characteristics of 11 rabies virus isolates in mice: titers and relative invasiveness of virus, incubation period of infection, and survival of mice with sequelae","volume":"136","author":"Baer","year":"1977","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2005.03.037_bib49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1073\/pnas.80.1.70","article-title":"Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus","volume":"80","author":"Dietzschold","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.vaccine.2005.03.037_bib50","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1128\/JVI.53.3.926-934.1985","article-title":"Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein","volume":"53","author":"Seif","year":"1985","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2005.03.037_bib51","first-page":"315","article-title":"Molecular epidemiology of lyssaviruses: focus on the glycoprotein and pseudogenes","volume":"60","author":"Tordo","year":"1993","journal-title":"Onderstepoort J Vet Res"},{"issue":"1","key":"10.1016\/j.vaccine.2005.03.037_bib52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1006\/viro.1993.1236","article-title":"Molecular diversity of the Lyssavirus genus","volume":"194","author":"Bourhy","year":"1993","journal-title":"Virology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X05004019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X05004019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T05:01:48Z","timestamp":1683090108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X05004019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":52,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0264410X05004019"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2005.03.037","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}